NCT06202131 Use of Ctdna in Patients With Gastrointestinal Tract Tumors
| NCT ID | NCT06202131 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Pancreas Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2028-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-11-01 with a primary completion date of 2028-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the use of ctDNA in the clinical management of patients with tumors of the gastrointestinal tract.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * PS ECOG \<2; * Histological diagnosis of gastrointestinal cancer: esophageal, gastric, intestinal, pancreatic, biliary tract neoplasms; * Radiological evidence of resectable/locally advanced/metastatic disease on the date of signing the written informed consent; * Adequate organ and function; * Availability of tumor histological material. Exclusion Criteria: * No histological diagnosis of neoplasia of the gastrointestinal tract. * No written informed consent.
Contact & Investigator
Lisa Sakvatore, MD, PhD
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06202131 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Pancreas Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06202131 currently recruiting?
Yes, NCT06202131 is actively recruiting participants. Contact the research team at lisa.salvatore@policlinicogemelli.it for enrollment information.
Where is the NCT06202131 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06202131 clinical trial?
NCT06202131 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Lisa Sakvatore, MD, PhD at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.